NL-OMON53566招募中4 期
Encorafenib/binimetiib master protocol: an open-label continuation study for participants continuing from encorafenib/binimetinib clinical studies. ;Sub-study 1: An open-label study for continued treatment access for participants from the C4211001 (Array CMEK162X2201) and the C4211003 (Array-162-311, MILO) Binimetinib studies.;Sub-study 2: An open-label study for continued treatment access for participants from the C4221004 (Array CMEK162B2301, Columbus) Encorafenib and Binimetinib study;Sub-s - FLOTILLA
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- Pfizer
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Any participant who is receiving study intervention and deriving clinical
- •benefit (as determined by the principal investigator) in an
- •encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03
- •Grade >=3 or intolerable Grade 2 AEs considered to be related to study
排除标准
- •1. Any medical reason that, in the opinion of the investigator or sponsor,
- •precludes the participant from inclusion in the study
研究者
相似试验
进行中（未招募）
1 期
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer.BRAF V600E-mutant Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000417-37-NLArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)90
招募中
2 期
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung CancerNL-OMON54680Array Biopharma Inc. (a wholly owned subsidiary of Pfizer Inc.)25
进行中（未招募）
1 期
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer.EUCTR2019-000417-37-ITARRAY BIOPHARMA INC.40
进行中（未招募）
1 期
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer.BRAF V600E-mutant Non-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000417-37-ESArray BioPharma Inc.40
已完成
2 期
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03915951Pfizer98